Navigation Links
ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer

Lung cancer, the header among all forms of cancer, is avenged now by the new proven effective ZD1839.

It has been shown that ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, has confirmed, durable responses and safety in patients with advanced non-small cell lung cancer (NSCLC) as monotherapy and in combination with standard chemotherapy agents after segmental scrutinization in two different studies.

Vincent Miller, MD, of Memorial Sloan-Kettering Cancer Center in New York and the principal investigator of the first study said, "It is hoped that our study will be a prelude to better outcomes for NSCLC patients in the near future." No novel toxicities were seen with ZD1839 treatment in combination with standard chemotherapy.

In a second study, which addressed intermittent dosing of ZD1839 in Japanese patients with advanced lung cancer, more than 20% of patients showed partial responses to ZD1839 between 1 and 11 months.

With such promising results, researchers are now working on whether this drug can be used for other forms of cancer as well.
'"/>




Page: 1

Related medicine news :

1. Study Proves That MMR Vaccine Is Not Connected To Autistic Babies
2. Pilot Study Proves Home Abortions ‘Safe’
3. Many Nonprescription Cough Medicines Proves Ineffective
4. Less Invasive By Pass Surgery Proves Economical In The Long Run
5. Epidural Mistakes Proves To Be Fatal Blunders
6. Combined Anti-Fever Drug Therapy Proves Unsafe for Childhood Fever
7. Drug Trial Proves Nightmare for British Indian Student
8. Naturopathic Care Proves Beneficial for TMD Pain
9. Medtronic Device Proves Effective in Parkinson’s Diseas
10. Large Community Spirometry Screening Proves Successful
11. Pregabalin Proves Durable Pain Relief Option for Fibromyalgia
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “The Journey: ... faced every danger possible to save lost souls in the Philippines. “The Journey: From ... Carole is a dedicated teacher of the Bible. She has taught all ages and ...
(Date:10/12/2017)... ... October 12, 2017 , ... First ... compliance program management, will showcase a range of technology and learning solutions at ... (NCAL) Convention and Expo to be held October 14–18, 2017 at the Mandalay ...
(Date:10/12/2017)... Orleans, LA (PRWEB) , ... October 12, 2017 , ... ... centers in the U.S., announced today its plans to open a flagship location in ... will occupy the former Rooms To Go store next to Office Depot in the ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), ... of an innovative new design of the shoulder pad. The shoulder pad provides ... while controlling your pain while using cold therapy. By utilizing ice and water that ...
Breaking Medicine News(10 mins):
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
Breaking Medicine Technology: